ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
06 févr. 2024 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
11 avr. 2023 07h00 HE
|
ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
08 mars 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
13 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
01 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
13 janv. 2022 07h00 HE
|
ONL Therapeutics
– Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – –...
ONL Therapeutics Announces First-In-Human Clinical Study with ONL1204
08 oct. 2019 07h00 HE
|
ONL Therapeutics
Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, Mich., Oct. 08, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
22 août 2019 11h54 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
22 août 2019 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First in Human Clinical Trials
18 juin 2019 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., June 18, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision in a range of retinal diseases, today...